Publication:
Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL'HIV Trial.

Simple item page
cris.virtual.author-orcid0000-0002-9094-9476
cris.virtualsource.author-orcidb256b53c-3915-4d75-8048-1c3f46cbbb42
cris.virtualsource.author-orcid6f8d808a-bd6f-4521-88a7-a2d4bdb11d3f
cris.virtualsource.author-orcid293ff41f-2638-4ba0-a342-626965287f31
cris.virtualsource.author-orcid261c592a-cd6e-4c32-b0f7-ca6c7ff7e96a
datacite.rightsopen.access
dc.contributor.authorMarinosci, Annalisa
dc.contributor.authorSculier, Delphine
dc.contributor.authorWandeler, Gilles
dc.contributor.authorYerly, Sabine
dc.contributor.authorStoeckle, Marcel
dc.contributor.authorBernasconi, Enos
dc.contributor.authorBraun, Dominique L
dc.contributor.authorVernazza, Pietro
dc.contributor.authorCavassini, Matthias
dc.contributor.authorDecosterd, Laurent
dc.contributor.authorGünthard, Huldrych F
dc.contributor.authorSchmid, Patrick
dc.contributor.authorLimacher, Andreas
dc.contributor.authorBranca, Mattia
dc.contributor.authorCalmy, Alexandra
dc.date.accessioned2024-12-18T11:00:22Z
dc.date.available2024-12-18T11:00:22Z
dc.date.issued2024-11
dc.description.abstractThe SIMPL'HIV study investigated whether switching to dolutegravir (DTG) + emtricitabine (FTC) was noninferior to continuing combined antiretroviral therapy for maintaining HIV-1 suppression at 144 weeks. The study demonstrated that viral suppression, CD4 gains, adverse events, quality of life, and patient satisfaction were comparable between groups, confirming DTG + FTC's safety and efficacy for long-term management of HIV-1 infection.
dc.description.numberOfPages5
dc.description.sponsorshipClinic of Infectiology
dc.description.sponsorshipDepartment of Clinical Research, Clinical Trials Unit Bern
dc.description.sponsorshipDepartment of Clinical Research (DCR) - Statistics & Methodology (Bütikofer)
dc.identifier.doi10.48620/78558
dc.identifier.pmid39507885
dc.identifier.publisherDOI10.1093/ofid/ofae618
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/189678
dc.language.isoen
dc.publisherOxford University Press
dc.relation.fundingSwiss National Science Foundation
dc.relation.fundingSwiss HIV Cohort Study Research Foundation
dc.relation.fundingSHCS Research Foundation
dc.relation.grantno166819, 17481, 177499
dc.relation.grantno826
dc.relation.ispartofOpen Forum Infectious Diseases
dc.relation.issn2328-8957
dc.subjectHIV-1 dual therapy
dc.subjectdolutegravir + emtricitabine
dc.subjectmaintenance treatment
dc.subjectpatient satisfaction
dc.subjectquality of life
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.titleEfficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL'HIV Trial.
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.issue11
oaire.citation.startPageofae618
oaire.citation.volume11
oairecerif.author.affiliationClinic of Infectiology
oairecerif.author.affiliationDepartment of Clinical Research, Clinical Trials Unit Bern
oairecerif.author.affiliationDepartment of Clinical Research (DCR) - Statistics & Methodology (Bütikofer)
oairecerif.author.affiliation2Institute of Social and Preventive Medicine
oairecerif.author.affiliation2Department of Clinical Research (DCR) - Statistics & Methodology
unibe.contributor.roleauthor
unibe.contributor.roleauthor
unibe.contributor.roleauthor
unibe.contributor.roleauthor
unibe.contributor.roleauthor
unibe.contributor.roleauthor
unibe.contributor.roleauthor
unibe.contributor.roleauthor
unibe.contributor.roleauthor
unibe.contributor.roleauthor
unibe.contributor.roleauthor
unibe.contributor.roleauthor
unibe.contributor.roleauthor
unibe.contributor.roleauthor
unibe.contributor.roleauthor
unibe.description.ispublishedpub
unibe.journal.abbrevTitleOpen Forum Infect Dis
unibe.refereedtrue
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
ofae618.pdf
Size:
453.76 KB
Format:
Adobe Portable Document Format
File Type:
text
License:
https://creativecommons.org/licenses/by/4.0
Content:
published
Download

Collections

Publications